African Swine Fever Virus Vaccine Development

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 1106

Special Issue Editors


E-Mail
Guest Editor
Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China
Interests: African swine fever virus; immune; immunotherapy; vaccine

E-Mail Website
Guest Editor
Beijing Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Beijing, China
Interests: African swine fever virus; ASFV vaccine; live vector vaccine

E-Mail Website
Guest Editor
Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China
Interests: animal vaccines; molecular immunology; innate immunity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

African Swine Fever Virus (ASFV) is a large, enveloped double-stranded DNA virus. ASFV is a highly infectious and severe hemorrhagic disease that affects pigs, causing a wide range of clinical signs. ASFV has a case fatality rate of up to 100% in domestic pigs and wild boars. This outbreak has led to the deaths and culling of millions of pigs, posing a significant threat to the global pig industry. Fortunately, vaccines with good safety and efficacy have been developed and are being licensed for use in some countries. Although a vaccine that involves the deletion of virulent genes has been licensed in Vietnam and is used in specific local areas and limited farms, there are concerns about its biosafety. Issues such as homologous recombination, delayed onset, and the potential for secondary infections pose significant risks, and the performance of the gene-deleted live vaccine still requires further study. While inactivated vaccines, subunit vaccines, and vector-based ASF vaccines are generally considered safer, their efficacy is not enough to protect against higher doses of virulent viruses in inoculated infections.

We must investigate the changes that occur during viral infection and the resulting pathogenesis, while also focusing on vaccine research to provide a solid foundation for preventing and controlling ASF.

This Special Issue will explore the pathogenicity of and vaccines related to ASFV infection. We welcome original research articles and reviews on topics including (but not limited to) the following areas:

  1. Virus infection and dissemination;
  2. Pathogenicity, migratory patterns, tissue tropism, and distribution in pigs;
  3. Research on immune responses and the protective effects of various types of ASF vaccines.

We look forward to receiving your contributions.

Dr. Faming Miao
Dr. Hong Jia
Dr. Lian-Feng Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • African swine fever virus
  • infection and damage
  • immune response
  • vaccine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1890 KB  
Review
Identification of T-Cell Epitopes and Vaccine Development for African Swine Fever Virus
by Wanyi Ni, Hanchun Yang and Nianzhi Zhang
Vaccines 2025, 13(9), 955; https://doi.org/10.3390/vaccines13090955 - 7 Sep 2025
Viewed by 677
Abstract
African swine fever virus (ASFV) has inflicted severe devastation on the global pig industry, yet a globally approved vaccine remains unavailable. Given that cellular immunity is critical for ASFV prevention, the development of vaccines based on T-cell epitopes emerges as a promising strategy [...] Read more.
African swine fever virus (ASFV) has inflicted severe devastation on the global pig industry, yet a globally approved vaccine remains unavailable. Given that cellular immunity is critical for ASFV prevention, the development of vaccines based on T-cell epitopes emerges as a promising strategy to control this virus. This review synthesizes the recent advancements and challenges in the research on ASFV T-cell epitopes, while offering insights into the potential impact of novel T-cell epitope-based vaccines. Notably, only a limited number of ASFV T-cell epitopes have been experimentally identified to date, covering fewer than 20 ASFV proteins. This bottleneck is attributed to challenges such as high swine leukocyte antigen (SLA) polymorphism, suboptimal accuracy of predicting tools, and complex experimental validation procedures. Although current studies on ASFV-specific T-cell immune responses and epitope identification are insufficient to meet vaccine development needs, continuous progress in T-cell immunology research in recent years has brought this goal closer to reality. Full article
(This article belongs to the Special Issue African Swine Fever Virus Vaccine Development)
Show Figures

Figure 1

Back to TopTop